NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the ...

New research, however, shows that Black children are less likely than white kids to complete such testing. This type of ...